| | |
Summary: In Vitro and In Vivo Evaluation of 64
Cu-TETA-Tyr3
-
Octreotate. A New Somatostatin Analog with
Improved Target Tissue Uptake
Jason S. Lewis,1
Ananth Srinivasan,2
Michelle A. Schmidt2
and Carolyn J. Anderson1,
*
1
MALLINCKRODT INSTITUTE OF RADIOLOGY, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, ST. LOUIS, MISSOURI, USA;
AND 2
MALLINCKRODT MEDICAL, INC., HAZELWOOD, MISSOURI, USA
ABSTRACT. Radiolabeled somatostatin analogs have demonstrated potential as cancer therapeutic agents.
Many of these agents are based on the analog octreotide (OC). Recently it has been shown that substitution
of a tyrosine for phenylalanine in the 3-position and changing the C-terminus from an alcohol to an acid
improves the targeting of somatostatin-rich tissues. The compound, 1,4,8,11-tetraazacyclotetradecane-
N,N ,N ,N -tetraacetic acid-Tyr3
-octreotate (TETA-Y3-TATE), was synthesized and radiolabeled with
|
